C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC) announced an inducement non-qualified stock option grant of 85,480 shares to one new employee, approved March 9, 2026. The exercise price equals the closing market price on the grant date. Vesting: four years with 25% after year one, then 36 monthly installments.

The grant was made as a material inducement under Nasdaq Listing Rule 5635(c)(4) and is subject to continued employment through each vesting date.

News Market Reaction – CCCC

-13.09%

94 alerts

-13.09% News Effect

+31.3% Peak in 5 hr 2 min

-$56M Valuation Impact

$372.75M Market Cap

1.2x Rel. Volume

On the day this news was published, CCCC declined 13.09%, reflecting a significant negative market reaction. Argus tracked a peak move of +31.3% during that session. Our momentum scanner triggered 94 alerts that day, indicating high trading interest and price volatility. This price movement removed approximately $56M from the company's valuation, bringing the market cap to $372.75M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -13.1% in the session following this news. A negative reaction despite the routine...

Analysis

The stock dropped -13.1% in the session following this news. A negative reaction despite the routine nature of an inducement grant would fit a pattern where not all company communications have been rewarded; one recent conference-related announcement was followed by a notable one-day decline. The company also maintains a $400,000,000 shelf registration for potential future financings, and equity compensation awards add to outstanding share-based overhang. Past news has often produced modest gains, so a sharp decline could represent a sentiment reset rather than a change in fundamentals.

Key Figures

Inducement options: 85,480 shares Grant date: March 9, 2026 Vesting period: 4 years +2 more

5 metrics

Inducement options 85,480 shares Non-qualified stock options granted to one new employee

Grant date March 9, 2026 Grant Date for inducement option award

Vesting period 4 years Options vest over four years subject to continued employment

Cliff vesting 25% 25% of shares vest on first anniversary of start date

Remaining installments 36 monthly installments Balance vests in 36 equal monthly installments thereafter

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 26	Earnings and update	Positive	+0.4%	Reported 2025 results, cash of $297.1M and runway to end of 2028.
Feb 23	Conference participation	Positive	+6.5%	Announced March 2026 conference presentations with investor webcasts.
Feb 23	Clinical trial update	Positive	+6.5%	First patient dosed in Phase 2 MOMENTUM trial of cemsidomide.
Feb 09	Inducement option grant	Neutral	+3.4%	Granted options for 162,880 shares to a new employee under inducement plan.
Feb 04	Conference appearance	Positive	-6.0%	Planned Guggenheim biotech summit fireside chat with webcast access.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and corporate updates have generally seen modest to strong positive price reactions, with one conference appearance headline coinciding with a notable decline.

Recent Company History

Over the past weeks, C4 Therapeutics has reported 2025 financials with a cash runway to the end of 2028, advanced cemsidomide into a Phase 2 MOMENTUM trial, and maintained active investor outreach via multiple healthcare conferences. A prior inducement option grant in February 2026 also drew attention. Price reactions to these updates ranged from modest gains around earnings to stronger moves on clinical and conference news, with one conference-related announcement followed by a sharp one-day decline.

Key Terms

nasdaq listing rule 5635(c)(4), non-qualified stock options, exercise price, inducement grant

4 terms

nasdaq listing rule 5635(c)(4) regulatory

"Inducement Grant was granted as a material inducement... in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-qualified stock options financial

"approved the grant of non-qualified stock options to purchase 85,480 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

exercise price financial

"The Inducement Grant has an exercise price per share that is equal to the closing price..."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

inducement grant financial

"approved the grant of non-qualified stock options... (the “Inducement Grant”)"

An inducement grant is a stock-based reward given to a new hire—often options or restricted shares—used as a recruiting “signing bonus” to encourage someone to join a company and stay long enough to add value. Investors care because these grants can dilute existing shareholdings, change executive incentives and increase reported compensation costs, so they signal both management priorities and potential impacts on shareholder value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 85,480 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on March 9, 2026 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with 25% of the shares vesting on the first-year anniversary of the employee’s start date, with the remainder of the shares vesting in thirty-six equal monthly installments thereafter, subject to the employee’s continued employment with C4T through each vesting date.

About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO^® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.

Contacts:
Investors: 
Courtney Solberg
Associate Director, Investor Relations
CSolberg@c4therapeutics.com

Media: 
Loraine Spreen 
Senior Director, Corporate Communications & Patient Advocacy 
LSpreen@c4therapeutics.com

FAQ

What did C4 Therapeutics (CCCC) announce on March 9, 2026 about an inducement grant?

C4 Therapeutics granted a non-qualified option for 85,480 shares to one new employee as an inducement. According to C4 Therapeutics, the grant was approved by independent directors under Nasdaq Listing Rule 5635(c)(4) and was made on the March 9, 2026 grant date.

How does the vesting schedule for the C4 Therapeutics (CCCC) inducement grant work?

The option vests over four years with 25% vesting at the one-year anniversary then monthly vesting thereafter. According to C4 Therapeutics, the remaining shares vest in thirty-six equal monthly installments subject to the employee remaining employed through each vesting date.

What exercise price was set for the C4 Therapeutics (CCCC) inducement grant on March 9, 2026?

The exercise price equals the closing price of C4 Therapeutics common stock on the grant date. According to C4 Therapeutics, the grant's per-share exercise price was set equal to the market close price on March 9, 2026.

Why was the inducement grant issued under Nasdaq Listing Rule 5635(c)(4) for C4 Therapeutics (CCCC)?

The grant was issued as a material inducement to hire a new employee under Nasdaq rules. According to C4 Therapeutics, independent directors approved the option grant in accordance with Nasdaq Listing Rule 5635(c)(4) to induce employment.